Physician profile
Patrick Hale Long
NPI 1780206094
$2,805.06
in general payments reported to CMS, 2019-2025
25 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.59 · 2023: $401 · 2024: $1,153 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $455.33 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $413.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $242.47 | 2024-2025 | |
| Pfizer INC. | $221.52 | 2023-2025 | |
| Corcept Therapeutics | $211.80 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $205.57 | 2023-2025 | |
| Lilly USA, LLC | $172.55 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $152.36 | 2023-2025 | Auvelity, Sunosi, Symbravo |
| Astrazeneca Pharmaceuticals LP | $111.53 | 2023-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $71.41 | 2023-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Phathom Pharmaceuticals, INC. | $66.56 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $63.70 | 2024-2025 | Arexvy, Shingrix, Pediarix |
| Sumitomo Pharma America, INC. | $58.59 | 2024-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $57.24 | 2024-2025 | |
| Amgen INC. | $48.31 | 2024-2025 | Repatha, Tavneos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.77 | 2024-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $36.69 | 2023 | Trintellix |
| Exact Sciences Corporation | $33.45 | 2024-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $28.42 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $22.78 | 2025 | Abilify Asimtufii |
| Xeris Pharmaceuticals, INC. | $20.96 | 2025 | Gvoke Hypopen |
| Harmony Biosciences LLC | $20.85 | 2023-2024 | Wakix |
| Astellas Pharma US INC | $19.58 | 2025 | Veozah |
| Viatris Specialty LLC | $15.66 | 2025 | Yupelri |
| Mylan Specialty L.P. | $15.65 | 2024 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.